Key statistics
On Friday, IDEAYA Biosciences Inc (IDYA:NSQ) closed at 31.28, 13.66% above the 52 week low of 27.52 set on Nov 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.85 |
---|---|
High | 31.49 |
Low | 29.83 |
Bid | 28.37 |
Offer | 35.00 |
Previous close | 29.99 |
Average volume | 762.98k |
---|---|
Shares outstanding | 86.43m |
Free float | 85.54m |
P/E (TTM) | -- |
Market cap | 2.70bn USD |
EPS (TTM) | -2.32 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- /C O R R E C T I O N -- IDEAYA Biosciences, Inc./
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
- IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
- IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
- IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
- IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
- IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
- IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
More ▼